PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis

15 May 2014
PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis

According to early results from a phase I study, a new targeted drug, PLX3397, appears remarkably active against a rare neoplastic joint disorder known as pigmented villonodular synovitis (PVNS).

The study evaluated patients whose disease had progressed despite all other available therapies.

More than three-quarters (79 percent) of the evaluable patients responded to the treatment, having a mean 61 percent reduction in tumour volume and rapid and substantial improvements in symptoms.

“These results are a shining example of how patients can experience a meaningful clinical benefit when we are able to match the right treatment with the right target,” said lead author William D. Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, NY.

“PLX3397 seemed to have a tremendous impact on the joint-destructive disease process as patients often reported a marked decrease in swelling and pain even very early in their treatment course.”

Approximately 600 people are affected by PVNS each year in the United States.

In these patients, tumours form in the joint cavity, leading to gradual destruction of the joint and debilitating symptoms.

Although it is characterised by an overgrowth of abnormal cells, PVNS is not referred to as a cancer per se, because it usually does not spread to other parts of the body.

PVNS typically affects the hip or knee, and tends to occur in younger persons.

Symptoms include joint swelling, pain, and reduced mobility.

While most patients are well managed with surgery, in some patients the disease comes back, necessitating additional surgery often requiring a joint replacement, and eventually advances to the point where it is no longer operable.

PLX3397 may be an effective new therapy option for such patients.

PLX3397 is a novel oral tyrosine kinase inhibitor that blocks several molecular targets including the colony stimulating factor 1 (CSF1) receptor.

In PVNS, a genetic abnormality causes the neoplastic cells to overproduce CSF1.

This recruits CSF1 receptor-bearing immune cells that fill and destroy the joint.

Therefore, PLX3397 blocks molecular pathways of the genetic abnormality that drives PVNS.

This may slow the destruction of the joint and also reduce the inflammation that accompanies the disease process.

Results from the first 23 patients treated on this single-arm, phase I study are being reported.

The patients had advanced PVNS with tumours in the knees, ankles, feet, or elbows.

Most of the patients have undergone multiple surgeries and some have received prior treatment with radiation and/or with other systemic targeted treatments such as imatinib or nilotinib.

The patients remained on the study until disease progression or inability to tolerate the drug.

Eleven out of 14 (79 percent) evaluable patients had tumour shrinkage sufficient to qualify as responders, and the disease was stable in the other three patients.

Patients had substantial improvements in overall joint functionality, as well as decreased pain and stiffness.

The drug was well tolerated.

The most common treatment-related side effects were hair colour changes, fatigue, nausea, swelling around the eyes, abnormal taste, diarrhoea, vomiting, and decreased appetite.

This research was supported by Plexxikon Inc.

ASCO Perspective

“While it’s still early, this study offers an exciting glimpse of the payoff of the precision medicine era, even for rare diseases like PVNS,” said Clifford A. Hudis, MD, FACP, ASCO President. 

“The research shows what’s possible when we unravel the molecular drivers of a disease and identify a drug that directly targets these defects.”

Source: ASCO